Century Targets FDA Filing for Diabetes Cell Therapy

Century Therapeutics, Inc. (IPSC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates · Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track f

BioPharma Dive roundup covers AstraZeneca’s eplontersen failure in a major heart disease study, boosting expectations for rival TTR amyloidosis drugs from Alnylam and BridgeBio. Other items include ARPA-H funding, GSK ending a neuroscience alliance with Alector, Vera Therapeutics’ FDA nod for IgA nephropathy, and Vertex’s $10B plan to buy Crinetics.

Century Therapeutics (NASDAQ: IPSC) presented new preclinical results for CNTY-813, an iPSC-derived islet replacement engineered with Allo-Evasion™ 5.0, at ADA 2026. The company said transplanted cells maintained normoglycemia for over eight months in mice, with glucose normalization within 60 minutes in glucose tolerance tests. It also reported >50% beta-cell composition, no tumorigenesis in >140 mice, and immune evasion in humanized models without immunosuppression. Century said Phase 1 manufa

The Walt Disney Company (DIS) filed a lawsuit against the FCC, alleging a retaliatory investigation. A judge denied an urgent hearing, setting a September 24 filing deadline. Disney reported Q3 revenue of $25.2B and operating income of $5.6B, with growth in streaming and experiences. The lawsuit's outcome may impact ABC's licenses and set precedents for political pressure on broadcasters.

Novo Nordisk (NYSE:NVO) submitted its oral Wegovy pill for regulatory review in China, trading at $45.88. Eli Lilly (NYSE:LLY) had previously submitted its rival pill. China's market for obesity treatments is expected to grow significantly. Novo has not disclosed approval or launch timelines. The stock trades 58.04% below its GF Value.

Alphabet (GOOGL) shares fell 0.7% to $339.76 after withdrawing a search-enforcement policy in 30 European markets to avoid potential 10% revenue penalties. The move follows an EU investigation into Google's practices, with the company trading 35.33% above its GF Value estimate.